Trials / Completed
CompletedNCT05362110
A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension
A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 361 (actual)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HCP1803 in patients with essential hypertension
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HCP1803-3 | Take it once daily for 8 weeks orally. |
| DRUG | RLD2002 | Take it once daily for 8 weeks orally. |
| DRUG | HPP2003-3 | Placebo drug. Take it once daily for 8 weeks orally. |
| DRUG | HPP2004 | Placebo drug. Take it once daily for 8 weeks orally. |
Timeline
- Start date
- 2022-05-16
- Primary completion
- 2023-06-05
- Completion
- 2023-06-05
- First posted
- 2022-05-05
- Last updated
- 2023-09-26
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05362110. Inclusion in this directory is not an endorsement.